ANAVEX publishes research on blarcamesine autophagy mechanism

Anavex Life Sciences Corp. (NASDAQ: AVXL) announced the publication of a peer-reviewed study in the journal iScience detailing the autophagy mechanism of its drug candidate blarcamesine through sigma-1 receptor activation.

The study, titled "Conserved LIR-specific interaction of Sigma-1 receptor and GABARAP," confirms the specific molecular mechanism by which blarcamesine restores impaired autophagy. The research identifies the sigma-1 receptor-localized motif responsible for interactions with autophagy proteins that promote autophagosome biogenesis and lysosome fusion.

Previous studies had established that blarcamesine restores impaired autophagy through sigma-1 receptor activation, demonstrating enhanced autophagic flux in human cells and in laboratory models. The current publication provides additional biochemical data detailing this mechanism.

"The interaction reported in this study could represent a missing biochemical link in autophagy modulation by S1R," said Juan Carlos Lopez-Talavera, the company's Head of Research and Development.

Anavex is developing blarcamesine for treatment of Alzheimer's disease, Parkinson's disease, and other central nervous system disorders. The drug candidate has completed Phase 2a and Phase 2b/3 clinical trials for Alzheimer's disease and Phase 2 studies in Parkinson's disease dementia and Rett syndrome.

The sigma-1 receptor has emerged as a target for treating neurodegeneration, with activation promoting autophagy and resulting in degradation of amyloid-beta precursor protein. The receptor is also involved in maintaining cellular functions and regulating calcium.

The research was conducted independently and published in iScience, a Cell Press journal. The findings build on earlier work demonstrating the autophagy restoration effects of sigma-1 receptor agonists in laboratory studies.

You May Also Be Interested In

• Synopsys (SNPS) PT Raised to $620 at Rosenblatt
• Nektar drug shows durability in skin disease trials at EADV 2026
• SharonAI secures $356M GPU-backed debt facility at 9.95%